FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TSCHÖPE, C.
Right arrow Articles by NOUTSIAS, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TSCHÖPE, C.
Right arrow Articles by NOUTSIAS, M.
(The FASEB Journal. 2004;18:828-835.)
© 2004 FASEB

Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene

CARSTEN TSCHÖPE1, THOMAS WALTHER, JENS KÖNIGER, FRANK SPILLMANN, DIRK WESTERMANN, FELICITAS ESCHER, MATTHIAS PAUSCHINGER, JOAO B. PESQUERO*, MICHAEL BADER{dagger}, HEINZ-PETER SCHULTHEISS and MICHEL NOUTSIAS

Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Charité-University Medicine, Free University of Berlin;
* Department of Biophysics, Universidade Federal de São Paulo, São Paulo, Brazil; and
{dagger} Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

1Correspondence: Charite-University Medicine, Campus Benjamin Franklin, Department of Cardiology and Pneumonology, Free University of Berlin, Hindenburgdamm 30, D-12220 Berlin, Germany. E-mail: ctschoepe{at}yahoo.com

Diabetic cardiomyopathy includes fibrosis. Kallikrein (KLK) can inhibit collagen synthesis and promote collagen breakdown. We investigated cardiac fibrosis and left ventricular (LV) function in transgenic rats (TGR) expressing the human kallikrein 1 (hKLK1) gene in streptozotocin (STZ) -induced diabetic conditions. Six weeks after STZ injection, LV function was determined in male Sprague-Dawley (SD) rats and TGR(hKLK1) (n=10/group) by a Millar tip catheter. Total collagen content (Sirius Red staining) and expression of types I, III, and VI collagen were quantified by digital image analysis. SD-STZ hearts demonstrated significantly higher total collagen amounts than normoglycemic controls, reflected by the concomitant increment of collagen types I, III, and VI. This correlated with a significant reduction of LV function vs. normoglycemic controls. In contrast, surface-specific content of the extracellular matrix, including collagen types I, III, and VI expression, was significantly lower in TGR(hKLK1)-STZ, not exceeding the content of SD and TGR(hKLK1) controls. This was paralleled by a preserved LV function in TGR(hKLK1)-STZ animals. The kallikrein inhibitor aprotinin and the bradykinin (BK) B2 receptor antagonist icatibant reduced the beneficial effects on LV function and collagen content in TGR(hKLK1)-STZ animals. Transgenic expression of hKLK1 counteracts the progression of LV contractile dysfunction and extracellular matrix remodeling in STZ-induced diabetic cardiomyopathy via a BK B2 receptor-dependent pathway.—Tschöpe, C., Walther, T., Königer, J., Spillmann, F., Westermann, D., Escher, F., Pauschinger, M., Pesquero, J. B., Bader, M., Schultheiss, H.-P., Noutsias, M. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene.


Key Words: diabetes mellitus • diabetic cardiomyopathy • kallikrein • pathogenesis • therapy • transgenic animal




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Riad, S. Jager, M. Sobirey, F. Escher, A. Yaulema-Riss, D. Westermann, A. Karatas, M. M. Heimesaat, S. Bereswill, D. Dragun, et al.
Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice
J. Immunol., May 15, 2008; 180(10): 6954 - 6961.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Van Linthout, F. Spillmann, A. Riad, C. Trimpert, J. Lievens, M. Meloni, F. Escher, E. Filenberg, O. Demir, J. Li, et al.
Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy
Circulation, March 25, 2008; 117(12): 1563 - 1573.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
D. Westermann, S. Van Linthout, S. Dhayat, N. Dhayat, F. Escher, C. Bucker-Gartner, F. Spillmann, M. Noutsias, A. Riad, H.-P. Schultheiss, et al.
Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy
Diabetes, July 1, 2007; 56(7): 1834 - 1841.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
D. Westermann, S. Rutschow, S. Jager, A. Linderer, S. Anker, A. Riad, T. Unger, H.-P. Schultheiss, M. Pauschinger, and C. Tschope
Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy: The Role of Angiotensin Type 1 Receptor Antagonism
Diabetes, March 1, 2007; 56(3): 641 - 646.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. Chandrashekhar
Embracing Diversity in Remodeling: A Step in Therapeutic Decision Making in Heart Failure?
J. Am. Coll. Cardiol., February 20, 2007; 49(7): 822 - 825.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. A. Gould, M. Yii, M. D. Esler, J. M. Power, and D. M. Kaye
Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure
Eur. Heart J., December 1, 2005; 26(23): 2562 - 2567.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. De Acetis, A. Notte, F. Accornero, G. Selvetella, M. Brancaccio, C. Vecchione, M. Sbroggio, F. Collino, B. Pacchioni, G. Lanfranchi, et al.
Cardiac Overexpression of Melusin Protects From Dilated Cardiomyopathy Due to Long-Standing Pressure Overload
Circ. Res., May 27, 2005; 96(10): 1087 - 1094.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by The Federation of American Societies for Experimental Biology.